Management of renal anemia in 2013;Prise en charge de l'anémie rénale en 2013

Revue Medicale Suisse

Volumn 9, Issue 375, 2013, Pages 462-467

  Gianella, Pietro ^a   Martin, Pierre Yves ^a   Stucker, Fabien ^b  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

^b HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; VITAMIN DEFICIENCY;

ANEMIA; ERYTHROPOIETIN; HUMANS; IRON METABOLISM DISORDERS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; NEPHROLOGY; RECOMBINANT PROTEINS;

EID: 84874584004     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Babitt JL, Lin H. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23: 1631-4.
2. Erslev AJ. Erythropoietin. N Engl J Med 1991;324: 1339-44.
3. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21: 2151-6.
4. Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 2002; 42: 1171-6.
5. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75: 976-81.
6. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010;5: 1681-9.
7. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 2010;55: 726-41.
8. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162: 1401-8. (Pubitemid 34655201)
9. World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. In: de Benoist B, McLean E, Egli I, Cogswell M (eds), 2008.
10. Stancu S, Barsan L, Stanciu A, et al. Can the response to iron therapy be predicted in anemic non dialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010;5: 409-16.
11. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996;7: 2654-7. (Pubitemid 27469573)
12. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis- associated hemosiderosis in the era of erythropoiesis- stimulating agents: A MRI study. Am J Med 2012; 125: 991-9.
13. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6: 77-83.
14. Drueke T, Witko-Sarsat V, Massy Z, et al. Fe therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106: 2212-7. (Pubitemid 35222215)
15. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16: 3070-80. (Pubitemid 44743505)
16. Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64: 572-8. (Pubitemid 36871928)
17. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin (NHS). N Engl J Med 1998; 339: 584-90. (Pubitemid 28385655)
18. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia (CREATE). N Engl J Med 2006; 355: 2071-84. (Pubitemid 44749316)
19. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease (CHOIR). N Engl J Med 2006;355: 2085-98. (Pubitemid 44749317)
20. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (TREAT). N Engl J Med 2009;361: 2019-32.
21. Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012;6: 163-89.
22. Macdougall IC. New anemia therapies: Translating novel strategies from bench to bedside. Am J Kidney Dis 2012;59: 444-51.
23. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115: 3616-24.